LIGHT: Immunotherapy for treatment of primary tumors and metastatic disease
University of Chicago, IL, United States
LIGHT is a multiâ€pronged immunotherapeutic approach for the treatment of cancer. LIGHT supercharges an antiâ€tumor immune response by recruiting immune cells to tumor sites and by stimulating T cell activation. LIGHT therapy destroys distant metastases and creates immune memory, blocking cancer recurrence.
Primary Application Area: Biotech & Biological Sciences
Technology Development Status: Concept
Technology Readiness Level: TRL 3
FIGURES OF MERIT
Value Proposition: LIGHT is a platform immuno-oncology therapeutic opportunity. Early studies suggest that LIGHT may be effective in patient subsets where current immunotherapies (CTLA4 and PD1) are not, because of its immune-cell recruiting mechanism of action.
Organization Type: Academic/Gov Lab
Showcase Booth #: 637
GOVT/EXTERNAL FUNDING SOURCES
Government Funding/Support to Date:
Primary Sources of Funding: Federal Grant
Looking for: Development / License Partners